In addition, GLP-1 RAs were shown to be effective in controlling symptoms of persistent hypercortisolemia in patients with CD, such as increased appetite, obesity, and dyslipidemia (65). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.